News

The company has established a clear plan, aiming to officially launch key registrational clinical trials in 2027. This strategic step marks a significant milestone in the development of its core therapies, laying a solid foundation for subsequent regulatory approvals and potential commercialization.

The funds will be disbursed in batches based on milestone events such as drug development progress, regulatory approval achievements, and market sales performance. This potential financial injection highlights the company's strategic positioning in the field of innovative therapies and also provides funding support for subsequent research and development.

The Federal Reserve Board on Monday proposed a recommendation to explicitly eliminate reputational risk from bank supervision and is seeking public comment. The proposal reaffirms the Federal Reserve's policy against penalizing or restricting institutions due to customers engaging in legal activities. Vice Chair Michelle W. Bowman stated that it is illegal for financial institutions to refuse customers based on political views, religious beliefs, or legal but unpopular businesses, and such practices should not exist within the Federal Reserve's supervisory framework. In June this year, the Federal Reserve announced that reputational risk would no longer be a component of bank supervisory reviews. This proposal aims to further ensure that supervisory decisions are based on substantive financial risks, while enhancing the clarity and precision of decision-making. Public comments must be submitted within 60 days after publication in the Federal Register.